Related Experiment Video
Updated: Jun 30, 2026
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Ensemble Machine Learning Approaches Predict Survival in Lower-Grade Glioma Based on Glycosphingolipid Gene
Jack W J Welland1, Janet E Deane1
1Cambridge Institute for Medical Research, Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK.
Computational and Structural Biotechnology Journal
|June 29, 2026
Summary
Machine learning models predict survival in lower-grade gliomas (LGGs) by analyzing glycosphingolipid (GSL) synthetic enzyme expression. This approach aids in risk stratification and understanding GSL roles in LGG pathology.
Area of Science:
- Biochemistry
- Oncology
- Computational Biology
Background:
- Glycosphingolipids (GSLs) are crucial membrane components involved in cell signaling.
- Altered GSL metabolism is linked to various cancers, but their specific roles in lower-grade gliomas (LGGs) are unclear.
Purpose of the Study:
- To investigate the role of GSLs in lower-grade gliomas (LGGs) and predict patient survival outcomes.
- To develop computational models for risk stratification in LGG patients.
Main Methods:
- Utilized ensemble machine learning approaches with transcriptomic data from LGG.
- Integrated GSL-specific metabolic simulations to predict survival outcomes.
- Analyzed GSL synthetic enzyme expression for risk stratification.
Main Results:
- The ensemble machine learning model effectively stratified LGG patients based on GSL synthetic enzyme expression.
- Identified correlations between GSL-modulated pathways (cell motility, division, Wnt signaling) and LGG pathology.
- Demonstrated the potential of machine learning in predicting survival outcomes for LGG.
Conclusions:
- GSL synthetic enzyme expression is a viable biomarker for risk stratification in LGG patients.
- GSL-related pathways play significant roles in LGG development and progression.
- GSL-based diagnostics and prognostics show promise for clinical application, pending experimental validation.
